卡利科辛的分子机制抑制了血管化
Zekun Zhou1, Yi Li1, Wei Jiang2
1College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China.
Nutrients
|January 11, 2024
概括
阿斯特拉加勒斯中的一种化合物卡利科辛通过增强细胞循环过程自来抑制血管化. 这项研究揭示了calycosin如何恢复化细胞的自,提供了一种新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管化 (VC) 是心血管疾病的一个标志,由血管光滑肌细胞骨质分化和酸沉积驱动.
- 向性自,一种细胞降解途径,是抑制VC和保持血管健康的有希望的策略.
- 虽然calycosin增强了巨细胞的自,但它在VC中的作用仍然未被探索.
研究的目的:
- 调查卡利科辛在抑制血管化的治疗潜力.
- 阐明卡利科辛对血管光滑肌细胞内自的作用的潜在机制.
主要方法:
- 在实验室中利用了老鼠胸前大动脉平滑肌肉细胞系 (A7r5) 作为血管化的模型.
- 评估了卡利科辛对骨质分化,沉积和自流的作用.
- 研究了卡利科辛对关键信号通路的影响,包括AMPK/mTOR和SNARE复合体的形成.
主要成果:
- 卡利科辛治疗在VC细胞模型中显著抑制了骨质分化和酸沉积.
- 卡利科辛通过激活AMPK/mTOR信号和恢复自细胞-溶酶体融合,增强了自细胞流量.
- 该化合物促进了可溶性N-乙基胺胺敏感因子附着蛋白受体 (SNARE) 复合体的形成,防止了自性阻塞.
结论:
- 卡利科辛有效地减轻了血管化,通过增强血管光滑肌细胞的自.
- 该机制涉及恢复自流并防止其在化的细胞中停止.
- 卡利科辛通过自调节为血管化提供了潜在的治疗剂.
相关概念视频
Calmodulin-dependent Signaling
5.1K
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
5.1K
Antihypertensive Drugs: Action of Calcium Channel Blockers
523
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
523
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
518
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
518
Overview of Secretory Vesicles
8.5K
Secretory vesicles, also known as dense core vesicles (DCVs), are membrane-bound vesicles that transport secretory proteins, such as hormones or neurotransmitters. Regulated secretory vesicles transport proteins from the trans-Golgi network to the exterior of the cell. Proteins present in regulated secretory vesicles are required to be rapidly exocytosed in large amounts upon a specific stimulus.
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
8.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Antihypertensive Drugs: Vasodilators
526
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
526


